B-cell lymphomas, version 5.2021. Featured updates to the NCCN guidelines

Academic Article


  • In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody–drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1–mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.
  • Authors

    Digital Object Identifier (doi)

    Author List

  • Zelenetz AD; Gordon LI; Chang JE; Christian B; Abramson JS; Advani RH; Bartlett NL; Budde LE; Caimi PF; de Vos S
  • Start Page

  • 1218
  • End Page

  • 1230
  • Volume

  • 19
  • Issue

  • 11